Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes
Study Details
Study Description
Brief Summary
Hypoglycemia is the main barrier for physical activity practice of patients with type 1 diabetes (T1D). For postprandial exercise, anticipation with meal insulin bolus reduction is the recommended method to reduce exercise-associated hypoglycemic risk. The impact of faster acting Aspart (FiAsp) pharmacokinetic on hypoglycemic risk has not yet been explored. This study will explore two different timings for exercise onset.
Objective: To compare the impact of rapid-acting insulin Aspart and faster acting Aspart (FiAsp) on glucose reduction during exercise.
Design: This study is a randomized, four-way, crossover study to compare the efficacy of 1) rapid-acting insulin Aspart, and 2) FiAsp on glucose reduction during an exercise performed 60 minutes or 120 minutes after breakfast. The insulin used and the timing of the exercise will be randomized. This project will be conducted at Institut de recherches cliniques de Montréal (IRCM, Montreal, Canada).
Hypothesis: Faster acting Aspart (FiAsp) will be non-inferior to insulin Aspart for hypoglycemic risk.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Aspart - 60-minutes postprandial exercise
|
Drug: Insulin Aspart
An insulin bolus of Aspart will be given 5 minutes before breakfast
Other: 60-minutes postprandial exercise
A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast
|
| Active Comparator: Aspart - 120-minutes postprandial exercise
|
Drug: Insulin Aspart
An insulin bolus of Aspart will be given 5 minutes before breakfast
Other: 120-minutes postprandial exercise
A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast
|
| Active Comparator: FiAsp - 60-minutes postprandial exercise
|
Drug: Insulin FiAsp
An insulin bolus of FiAsp will be given 5 minutes before breakfast
Other: 60-minutes postprandial exercise
A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast
|
| Active Comparator: FiAsp - 120-minutes postprandial exercise
|
Drug: Insulin FiAsp
An insulin bolus of FiAsp will be given 5 minutes before breakfast
Other: 120-minutes postprandial exercise
A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast
|
Outcome Measures
Primary Outcome Measures
- Decrease in plasma glucose levels during exercise [60 minutes (exercise period)]
Difference between glucose levels at the beginning of the exercise and the lowest glucose levels from the start of the exercise until the end of the exercise
Secondary Outcome Measures
- Percentage of time of plasma glucose levels spent below 4 mmol/L [60 minutes (exercise period)]
- Decremental area under the curve of plasma glucose levels [60 minutes (exercise period)]
- Area under the curve of plasma glucose levels below 4 mmol/L [60 minutes (exercise period)]
- Number of patients with an exercise-induced hypoglycemia below 3.9 mmol/L [60 minutes (exercise period)]
- Number of patients with an exercise-induced hypoglycemia below 3.3 mmol/L [60 minutes (exercise period)]
- Number of patients requiring an oral treatment for hypoglycemia [60 minutes (exercise period)]
- Total number of hypoglycemia episodes requiring treatment [60 minutes (exercise period)]
- Percentage of time of plasma glucose levels spent above 10 mmol/L [60 minutes (exercise period)]
- Percentage of time of plasma glucose levels spent between 4 and 10 mmol/L [60 minutes (exercise period)]
- Mean time (minutes) to the first hypoglycemic event [60 minutes (exercise period)]
- Amount of carbohydrates needed to treat a hypoglycemic event [60 minutes (exercise period)]
- Change in oxyhemoglobin in the vastus lateralis [60 minutes (exercise period)]
- Changes in deoxyhemoglobin in the vastus lateralis [60 minutes (exercise period)]
- Changes in total hemoglobin in the vastus lateralis [60 minutes (exercise period)]
- Percentage of time of plasma glucose levels spent between 4 and 10 mmol/L [90 minutes after the end of exercise]
- Percentage of time of plasma glucose levels spent below 4 mmol/L [90 minutes after the end of exercise]
- Percentage of time of plasma glucose levels spent above 10 mmol/L [90 minutes after the end of exercise]
- Area under the curve of plasma glucose levels below 4 mmol/L [90 minutes after the end of exercise]
- Number of patients requiring an oral treatment for hypoglycemia [90 minutes after the end of exercise]
- Total number of hypoglycemia episodes requiring treatment [90 minutes after the end of exercise]
- Total amount of carbohydrates needed to treat hypoglycemic events [90 minutes after the end of exercise]
- Area under the curve of plasma glucose levels [4.5 hours (entire protocol period)]
- Total number of hypoglycemia episodes requiring treatment [4.5 hours (entire protocol period)]
- Total amount of carbohydrates needed to treat hypoglycemic events [4.5 hours (entire protocol period)]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Males and females ≥ 18 years of old.
-
Clinical diagnosis of type 1 diabetes for at least one year.
-
HbA1c ≤ 9.5%.
-
Patients using multiple daily injections with basal-bolus insulin regimen and insulin analogs (pre-meal: Aspart, Lispro, Guilisine or Fiasp; basal: Detemir, Glargine U100 & U300, Degludec U100).
-
Written informed consent given.
Exclusion Criteria:
-
Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator.
-
Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
-
Anemia (Hb < 100g/L).
-
Ongoing pregnancy or breastfeeding.
-
Severe hypoglycemic episode within two weeks of screening.
-
Other serious medical illness likely to interfere with study participation or with the ability to complete the exercise periods by the judgment of the investigator (e.g. orthopedic limitation).
-
Ongoing treatment with CSII (Continuous Subcutaneous Insulin Infusion) "insulin pump therapy".
-
Participation to a clinical trial in the last 3 months prior to inclusion in this study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Institut de recherches cliniques de Montréal | Montréal | Quebec | Canada | H2W 1R7 |
Sponsors and Collaborators
- Institut de Recherches Cliniques de Montreal
Investigators
- Principal Investigator: Remi Rabasa-Lhoret, Institut de recherches cliniques de Montréal
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FiAsp-Exercise